Senolytic Compounds: Quercetin, Fisetin, and Clearing Senescent Cells — Research Status

Senescent Cells and Aging

Cellular senescence is a state in which cells permanently stop dividing but don't die. Senescent cells:

• Accumulate progressively with age in virtually all tissues
• Secrete inflammatory cytokines, proteases, and other factors collectively called the SASP (Senescence-Associated Secretory Phenotype)
• Impair tissue function, promote chronic inflammation ("inflammaging"), and may contribute to age-related disease

The initial discovery that clearing senescent cells in genetically engineered mice dramatically improved healthspan (Baker et al., Nature, 2011) launched the senolytic field. The research question became: can we do this pharmacologically?

First-Generation Senolytics: Dasatinib + Quercetin

The first identified senolytic drug combination came from the Mayo Clinic group of James Kirkland. A 2015 paper in Aging Cell (Zhu et al.) used bioinformatic analysis of anti-apoptotic pathways active in senescent cells to identify potential senolytics, then tested them in cell culture and animal models.

Dasatinib (a cancer drug, BCR-ABL inhibitor) and quercetin (a plant polyphenol) together cleared senescent cells more effectively than either alone and improved physical function in old mice.

This combination — D+Q — became the benchmark in the field.

Quercetin: The Accessible Component

Quercetin is a flavonoid found in onions, capers, apples, grapes, broccoli, and many other foods. It's been researched extensively for anti-inflammatory and antioxidant properties.

Senolytic Mechanism

In senescent cells, quercetin appears to interfere with several anti-apoptotic pathways that allow senescent cells to resist cell death despite ongoing stress:

• Inhibition of PI3K/AKT/mTOR survival signaling
• BCL-2 family protein modulation
• p53 pathway interaction

Human Data

A 2019 pilot study (Kirkland et al., EBioMedicine) in 9 patients with idiopathic pulmonary fibrosis (IPF) — a disease where senescent cells are implicated — found that 3 weeks of intermittent dasatinib + quercetin (D+Q) treatment:

• Reduced circulating senescent cell burden (measured by p16 and p21 markers)
• Improved 6-minute walk distance
• Improved gait speed and chair-rise time

This was a small, uncontrolled pilot, but the functional improvements were meaningful.

Subsequent trials in different populations (including a Mayo Clinic RCT in older adults) are ongoing. Results from several larger trials are expected in 2024–2026.

Fisetin: The Emerging Senolytic

Fisetin is a flavonoid found primarily in strawberries, apples, mangoes, kiwi, peaches, and cucumbers. It was identified as a potent senolytic in a 2018 EBioMedicine paper (Yousefzadeh et al.) from Mayo Clinic that screened 10 flavonoids for senolytic activity.

Key Finding

In that 2018 study, fisetin was found to:

• Have the highest senolytic activity among flavonoids tested
• Reduce senescent cell burden in multiple mouse tissues
• Extend median lifespan by 10% in old mice (treated starting at 85 weeks of age)
• Improve health status and reduced pathology in aging mice

The researchers found fisetin restored tissue homeostasis and reduced markers of senescence (SA-β-gal, p21, p16) across multiple tissues.

Human Data

A 2021 clinical trial at Mayo Clinic (Kirkland/Tchkonia lab) of high-dose fisetin (20mg/kg for two consecutive days, monthly) in older adults is underway. Preliminary results have been promising for tolerability but full efficacy data is not yet published at scale.

A 2022 pilot study in older patients with Alzheimer's disease found fisetin supplementation (1000mg/day for 6 months) was safe and tolerable, with some improvements in cognitive markers and serum senescence markers.

Dosing Protocols in Senolytic Research

An important concept in senolytic research: intermittent pulsed dosing, not daily supplementation. Senolytics are proposed to work by triggering apoptosis in senescent cells during the dosing period; continuous dosing is not necessary (and may cause unwanted effects on non-senescent cells).

The research protocols typically use:

• Dasatinib + quercetin: Short courses (e.g., 2–5 consecutive days, then off for 1–3 months)
• Fisetin: 2 consecutive days at high doses per month, or similar short-course approaches

This differs fundamentally from daily antioxidant supplementation. The "pulse and clear" model is derived from the biology of senescent cell accumulation and clearance.

What This Means Practically

The senolytic field is genuinely exciting and the biology is well-grounded. The practical picture for 2026:

• The most interesting accessible compounds are fisetin and quercetin
• Both have plausible senolytic mechanisms and early human safety data
• Neither has large-scale RCT efficacy data in healthy aging humans yet
• The intermittent pulsed-dosing protocol is more consistent with the research framework than daily use
• Fisetin has higher senolytic potency than quercetin in the comparative studies

Related: Senolytics and Zombie Cells: Can You Clear the Damage of Aging? · Resveratrol: The Longevity Compound That Over-Promised — An Honest Research Review · Intermittent Fasting Calculator